174 related articles for article (PubMed ID: 32623836)
41. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
[TBL] [Abstract][Full Text] [Related]
42. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
43. Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.
Mathieu AL; Sperandio O; Pottiez V; Balzarin S; Herlédan A; Elkaïm JO; Fogeron ML; Piveteau C; Dassonneville S; Deprez B; Villoutreix BO; Bonnefoy N; Leroux F
J Biomol Screen; 2014 Aug; 19(7):1035-46. PubMed ID: 24809353
[TBL] [Abstract][Full Text] [Related]
44. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
45. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
46. Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry.
Clerc P; Carey GB; Mehrabian Z; Wei M; Hwang H; Girnun GD; Chen H; Martin SS; Polster BM
PLoS One; 2012; 7(8):e42487. PubMed ID: 22880001
[TBL] [Abstract][Full Text] [Related]
47. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.
Bogenberger JM; Delman D; Hansen N; Valdez R; Fauble V; Mesa RA; Tibes R
Leuk Lymphoma; 2015 Jan; 56(1):226-9. PubMed ID: 24707940
[No Abstract] [Full Text] [Related]
48. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.
Reynoso D; Nolden LK; Yang D; Dumont SN; Conley AP; Dumont AG; Zhou K; Duensing A; Trent JC
Mol Oncol; 2011 Feb; 5(1):93-104. PubMed ID: 21115411
[TBL] [Abstract][Full Text] [Related]
49. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
Kuriyama T; Kawano N; Yamashita K; Ueda A
J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
[TBL] [Abstract][Full Text] [Related]
50. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
51. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
52. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
[TBL] [Abstract][Full Text] [Related]
53. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
[TBL] [Abstract][Full Text] [Related]
54. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.
Stolz C; Hess G; Hähnel PS; Grabellus F; Hoffarth S; Schmid KW; Schuler M
Blood; 2008 Oct; 112(8):3312-21. PubMed ID: 18689543
[TBL] [Abstract][Full Text] [Related]
55. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
[TBL] [Abstract][Full Text] [Related]
56. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
[TBL] [Abstract][Full Text] [Related]
57. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.
Al-Harbi S; Hill BT; Mazumder S; Singh K; Devecchio J; Choudhary G; Rybicki LA; Kalaycio M; Maciejewski JP; Houghton JA; Almasan A
Blood; 2011 Sep; 118(13):3579-90. PubMed ID: 21772052
[TBL] [Abstract][Full Text] [Related]
58. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
59. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
[TBL] [Abstract][Full Text] [Related]
60. Targeting multiple arms of the apoptotic regulatory machinery.
Dai Y; Grant S
Cancer Res; 2007 Apr; 67(7):2908-11. PubMed ID: 17409392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
